Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 9 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
The University of Copenhagen has 11 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 11 distinct examiners across 10 distinct art units. This one-to-one ratio between the 11 pending actions and 11 distinct examiners indicates that every active matter is being reviewed by a different individual, preventing any single examiner from having a disproportionate impact on the portfolio.
The busiest examiner, SAIDHA, TEKCHAND, is responsible for 1 pending office action. This matches the workload of every other examiner involved, as the 11 pending office actions are spread perfectly across 11 distinct examiners. Navigating 10 distinct art units requires the university to address a variety of technical requirements and examination styles within the pharmaceutical field.
With 11 pending office actions currently in progress, the university maintains a broad front of intellectual property development. The involvement of 10 distinct art units suggests that the underlying technologies are diverse enough to fall under multiple specialized classifications. Practitioners must account for the perspectives of 11 different examiners to successfully advance these 11 pending actions.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (18%) |
| §103 only | 1 (9%) |
| §102 only | 1 (9%) |
| §112 only | 1 (9%) |
| Multi-statute (no §101) | 5 (45%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| SAIDHA, TEKCHAND | 1 | 82.9% | +14.0% |
| BARRETT, RYAN S | 1 | 65.6% | +40.9% |
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
| SCHLIENTZ, LEAH H | 1 | 41.8% | +38.7% |
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18762269 | GENERATION OF GLUCOSE-RESPONSIVE BETA CELLS | BARRON, SEAN C | 6d |
| 18041827 | EXTRACORPOREAL CLEARING TRAPS BASED ON INVERSE ELECTRON DEMAND DIELS-ALDER CYCLOADDITION FOR (PRE)-TARGETED THERAPY AND DIAGNOSTICS | SCHLIENTZ, LEAH H | 39d |
| 18566290 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | BOWERS, ERIN M | 70d |
| 18721990 | IMPROVED HEPARAN SULFATE AND METHODS OF MAKING THE SAME | SAIDHA, TEKCHAND | — |
| 18564398 | PEPTIDES DERIVED FROM RUMINOCOCCUS TORQUES | STEELE, AMBER D | — |
| 18038044 | CRISPR/CAS SCREENING SYSTEM MATERIALS AND METHODS | TRAN, KHOA NHAT | — |
| 17768525 | Agonist of Tacr2 | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18762269 | GENERATION OF GLUCOSE-RESPONSIVE BETA CELLS | BARRON, SEAN C | 6d |
| 18041827 | EXTRACORPOREAL CLEARING TRAPS BASED ON INVERSE ELECTRON DEMAND DIELS-ALDER CYCLOADDITION FOR (PRE)-TARGETED THERAPY AND DIAGNOSTICS | SCHLIENTZ, LEAH H | 39d |
| 18721990 | IMPROVED HEPARAN SULFATE AND METHODS OF MAKING THE SAME | SAIDHA, TEKCHAND | — |
| 18683341 | A METHOD OF MANIPULATING A QUBIT AND AN ASSEMBLY COMPRISING A QUBIT | BARRETT, RYAN S | — |
| 18038044 | CRISPR/CAS SCREENING SYSTEM MATERIALS AND METHODS | TRAN, KHOA NHAT | — |
| 18166339 | CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN | SHOMER, ISAAC | — |
| 17907455 | A FLEXIBLE FOIL FOR THE DELIVERY OF THERAPEUTIC CARGOS | KWON, JOHN SEUNGJAI | — |
| 17768525 | Agonist of Tacr2 | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 1654 | 2 |
| 1652 | 1 |
| 2148 | 1 |
| 1658 | 1 |
| 1632 | 1 |
| 1618 | 1 |
| 1612 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18762269 | GENERATION OF GLUCOSE-RESPONSIVE BETA CELLS | BARRON, SEAN C | 1653 | §102§112Other | Final Rejection | 6d | Pending | Jul 02, 2024 |
| 18721990 | IMPROVED HEPARAN SULFATE AND METHODS OF MAKING THE SAME | SAIDHA, TEKCHAND | 1652 | §102§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18683341 | A METHOD OF MANIPULATING A QUBIT AND AN ASSEMBLY COMPRISING A QUBIT | BARRETT, RYAN S | 2148 | §102Other | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18566290 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | BOWERS, ERIN M | 1653 | §102§112 | Final Rejection | 70d | Pending | Dec 01, 2023 |
| 18564398 | PEPTIDES DERIVED FROM RUMINOCOCCUS TORQUES | STEELE, AMBER D | 1658 | §101§112 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18038044 | CRISPR/CAS SCREENING SYSTEM MATERIALS AND METHODS | TRAN, KHOA NHAT | 1632 | §101§103 | Final Rejection | — | Pending | May 22, 2023 |
| 18041827 | EXTRACORPOREAL CLEARING TRAPS BASED ON INVERSE ELECTRON DEMAND DIELS-ALDER CYCLOADDITION FOR (PRE)-TARGETED THERAPY AND DIAGNOSTICS | SCHLIENTZ, LEAH H | 1618 | §103§112 | Non-Final OA | 39d | Pending | Feb 16, 2023 |
| 18166339 | CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN | SHOMER, ISAAC | 1612 | Other | Non-Final OA | — | Pending | Feb 08, 2023 |
| 17907455 | A FLEXIBLE FOIL FOR THE DELIVERY OF THERAPEUTIC CARGOS | KWON, JOHN SEUNGJAI | 1615 | §103 | Final Rejection | — | Pending | Sep 27, 2022 |
| 17768525 | Agonist of Tacr2 | BEANE, RANDALL L | 1654 | §102§103 | Final Rejection | — | Pending | Apr 13, 2022 |
| 17188805 | GIP PEPTIDE ANALOGUES | DABKOWSKI, ERINNE R | 1654 | §112Other | Final Rejection | 29d | Pending | Mar 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Copenhagen has 11 pending office actions as of October 2026, spread across 9 art units and 11 examiners.
Sean C Barron has the most, with 1 of University of Copenhagen's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
